As of 2024-12-12, the EV/EBITDA ratio of Diagonal Bio AB (DIABIO.ST) is -0.36. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. DIABIO.ST's latest enterprise value is 3.82 mil SEK. DIABIO.ST's TTM EBITDA according to its financial statements is -10.55 mil SEK. Dividing these 2 quantities gives us the above DIABIO.ST EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 5.2x - 7.8x | 6.5x |
| Forward P/E multiples | 6.0x - 9.1x | 7.6x |
| Fair Price | (0.19) - (0.25) | (0.22) |
| Upside | -847.2% - -1080.1% | -977.5% |
| Date | EV/EBITDA |
| 2024-12-10 | -0.36 |
| 2024-12-09 | -0.20 |
| 2024-12-06 | -0.25 |
| 2024-12-05 | -0.36 |
| 2024-12-04 | -0.29 |
| 2024-12-03 | -0.47 |
| 2024-12-02 | -0.50 |
| 2024-11-29 | -0.56 |
| 2024-11-28 | -0.48 |
| 2024-11-27 | -0.52 |
| 2024-11-26 | -0.56 |
| 2024-11-25 | -0.58 |
| 2024-11-22 | -0.62 |
| 2024-11-21 | -0.59 |
| 2024-11-20 | -0.60 |
| 2024-11-19 | -0.64 |
| 2024-11-18 | -0.68 |
| 2024-11-15 | -0.59 |
| 2024-11-14 | -0.64 |
| 2024-11-13 | -0.74 |
| 2024-11-12 | -0.65 |
| 2024-11-11 | -0.63 |
| 2024-11-08 | -0.68 |
| 2024-11-07 | -0.71 |
| 2024-11-06 | -0.56 |
| 2024-11-05 | -0.60 |
| 2024-11-04 | -0.72 |
| 2024-11-01 | -0.81 |
| 2024-10-31 | -0.87 |
| 2024-10-30 | -0.75 |
| 2024-10-29 | -0.68 |
| 2024-10-28 | -0.79 |
| 2024-10-25 | -0.91 |
| 2024-10-24 | -0.80 |
| 2024-10-23 | -0.65 |
| 2024-10-22 | -0.79 |
| 2024-10-21 | -0.65 |
| 2024-10-18 | -0.76 |
| 2024-10-17 | -0.80 |
| 2024-10-16 | -0.73 |
| 2024-10-15 | -0.76 |
| 2024-10-14 | -0.82 |
| 2024-10-11 | -0.91 |
| 2024-10-10 | -0.53 |
| 2024-10-09 | -0.65 |
| 2024-10-08 | -0.50 |
| 2024-10-07 | -0.56 |
| 2024-10-04 | -0.26 |
| 2024-10-03 | 0.13 |
| 2024-10-02 | 0.14 |